Overview

The marketing authorisation for Imatinib Teva B.V. has been withdrawn at the request of the marketing authorisation holder.

  •  

Imatinib Teva B.V. : EPAR - Summary for the public

български (BG) (304.52 KB - PDF)
español (ES) (254.87 KB - PDF)
čeština (CS) (295.18 KB - PDF)
dansk (DA) (252.87 KB - PDF)
Deutsch (DE) (255.81 KB - PDF)
eesti keel (ET) (250.8 KB - PDF)
ελληνικά (EL) (310.78 KB - PDF)
français (FR) (257.06 KB - PDF)
hrvatski (HR) (266.33 KB - PDF)
italiano (IT) (251.59 KB - PDF)
latviešu valoda (LV) (289.09 KB - PDF)
lietuvių kalba (LT) (272.09 KB - PDF)
magyar (HU) (287.15 KB - PDF)
Malti (MT) (293.87 KB - PDF)
Nederlands (NL) (254.9 KB - PDF)
polski (PL) (289.62 KB - PDF)
português (PT) (255.85 KB - PDF)
română (RO) (272.09 KB - PDF)
slovenčina (SK) (292.13 KB - PDF)
slovenščina (SL) (282.49 KB - PDF)
Suomi (FI) (254.63 KB - PDF)
svenska (SV) (253.32 KB - PDF)

Product information

Imatinib Teva B.V. : EPAR - Product Information

български (BG) (3.29 MB - PDF)
español (ES) (1.81 MB - PDF)
čeština (CS) (2.38 MB - PDF)
dansk (DA) (1.68 MB - PDF)
Deutsch (DE) (1.82 MB - PDF)
eesti keel (ET) (1.7 MB - PDF)
ελληνικά (EL) (3.69 MB - PDF)
français (FR) (1.81 MB - PDF)
hrvatski (HR) (1.79 MB - PDF)
íslenska (IS) (1.75 MB - PDF)
italiano (IT) (2.08 MB - PDF)
latviešu valoda (LV) (2.72 MB - PDF)
lietuvių kalba (LT) (2.28 MB - PDF)
magyar (HU) (2.6 MB - PDF)
Malti (MT) (3.11 MB - PDF)
Nederlands (NL) (1.88 MB - PDF)
norsk (NO) (1.75 MB - PDF)
polski (PL) (2.57 MB - PDF)
português (PT) (1.63 MB - PDF)
română (RO) (1.92 MB - PDF)
slovenčina (SK) (2.49 MB - PDF)
slovenščina (SL) (2.58 MB - PDF)
Suomi (FI) (1.78 MB - PDF)
svenska (SV) (1.75 MB - PDF)

Latest procedure affecting product information: -

08/05/2018

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Imatinib Teva B.V. : EPAR - All Authorised presentations

български (BG) (267.55 KB - PDF)
español (ES) (192.96 KB - PDF)
čeština (CS) (215.96 KB - PDF)
dansk (DA) (194.13 KB - PDF)
Deutsch (DE) (188.59 KB - PDF)
eesti keel (ET) (181.81 KB - PDF)
ελληνικά (EL) (254.63 KB - PDF)
français (FR) (190.31 KB - PDF)
hrvatski (HR) (212.27 KB - PDF)
íslenska (IS) (190.66 KB - PDF)
italiano (IT) (184.05 KB - PDF)
latviešu valoda (LV) (234.62 KB - PDF)
lietuvių kalba (LT) (209.4 KB - PDF)
magyar (HU) (219.56 KB - PDF)
Malti (MT) (219.47 KB - PDF)
Nederlands (NL) (194.63 KB - PDF)
norsk (NO) (191.93 KB - PDF)
polski (PL) (216.04 KB - PDF)
português (PT) (191.85 KB - PDF)
română (RO) (204.92 KB - PDF)
slovenčina (SK) (219.24 KB - PDF)
slovenščina (SL) (217.77 KB - PDF)
Suomi (FI) (184.79 KB - PDF)
svenska (SV) (186.7 KB - PDF)

Product details

Name of medicine
Imatinib Teva B.V.
Active substance
imatinib mesilate
International non-proprietary name (INN) or common name
imatinib
Therapeutic area (MeSH)
  • Dermatofibrosarcoma
  • Gastrointestinal Stromal Tumors
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anatomical therapeutic chemical (ATC) code
L01XE01

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Imatinib Teva B.V. is indicated for the treatment of:

  • Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
  • Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
  • Adult patients with Ph+ CML in blast crisis.
  • Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
  • Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  •  Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  • Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

Imatinib Teva B.V. is indicated for:

  • The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
  • The adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
  • The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

Authorisation details

EMA product number
EMEA/H/C/004748

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Teva B.V.

Swensweg
2031 GA
Haarlem
Netherlands

Marketing authorisation issued
15/11/2017

Assessment history

Imatinib Teva B.V. : EPAR - Public assessment report

CHMP summary of positive opinion for Imatinib Teva B.V.

This page was last updated on

How useful do you find this page?